Published within
|«
«
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
8
|
»
»|
| Type |
Product title / description
|
Pub
|
Price |
Expert View
|
New clinical trial data for canagliflozin have revealed that its blood glucose-lowering abilities show superiority to blockbuster gold-standard Januvia, with the added benefit of weight loss. The potential for first-to-market SGLT-2 inhibitor status in the US and its good safety and efficacy profile boost canagliflozin's chances for success in a crowded diabetes market.
Published By Datamonitor
|
14 Jun 2012 |
|
Expert View
|
New clinical data were presented at APA 2012 that showed that Latuda is effective as an adjunctive treatment for bipolar depression and may possess a procognitive effect in schizophrenia patients. These findings set Latuda apart from the competition and may allow the drug to shine in a fiercely competitive antipsychotics market.
Published By Datamonitor
|
15 May 2012 |
|
Expert View
|
Pooled data released at the APA 2012 suggest that Forest's Viibryd combines a fast onset of antidepressant activity with a favorable side-effect profile, satisfying two important unmet needs in depression pharmacotherapy. Conversely, results from the Phase III program for levomilnacipran are less impressive, suggesting that the drug offers little benefit over other drugs in its class.
Published By Datamonitor
|
15 May 2012 |
|
Expert View
|
Forest and Gedeon's cariprazine is a pharmacologically unique atypical antipsychotic in Phase III development for both schizophrenia and bipolar mania. Data presented at APA 2012 hint that while cariprazine appears to be effective in both indications, its tolerability and failure to address the broader bipolar depression patient population will hinder uptake.
Published By Datamonitor
|
15 May 2012 |
|
Expert View
|
The DSM-5, the latest edition of the gold-standard diagnostic guidelines in psychiatry throughout the world, is due to be unveiled in May 2013. Given the huge size of the psychiatry drug market, any changes made to the diagnoses of conditions such as depression, bipolar disorders, and schizophrenia - however slight - will be of great interest to the pharmaceutical industry.
Published By Datamonitor
|
15 May 2012 |
|
Expert View
|
In keeping with American Academy of Neurology meetings of recent years, multiple sclerosis once again dominated proceedings at AAN 2012. Novartis used the platform to present new data from the extension FREEDOMS II trial to support the long-term use of Gilenya, and provided Phase II results for siponimod in relapse remitting multiple sclerosis.
Published By Datamonitor
|
03 May 2012 |
|
Expert View
|
At AAN 2012, Merck Serono presented data from a long-term study showing that early Rebif treatment significantly reduced the clinical progression of multiple sclerosis. However, early intervention should be used cautiously to avoid unnecessary treatment.
Published By Datamonitor
|
03 May 2012 |
|
CommentWire
|
Insys Therapeutics' Subsys represents the first oral spray formulation to gain US approval for the treatment of breakthrough cancer pain. The drug's rapid onset of analgesic action and ease of administration offer distinct clinical benefits to patients. However, Subsys will face strong competition from generic Actiq and other rapidly acting fentanyl brands upon launch.
Published By Datamonitor
|
06 Jan 2012 |
|
CommentWire
|
New top-line data show that the innovative nicotinic receptor antagonist TC-5214 has once again failed to demonstrate efficacy as an add-on to antidepressants in patients with major depressive disorder. Approval now seems highly unlikely, leaving Targacept without a lead candidate and AstraZeneca with a hefty loss.
Published By Datamonitor
|
20 Dec 2011 |
|
CommentWire
|
Targacept's investigational neuronal nicotinic receptor agonist has failed to meet its primary endpoint in a Phase II trial in adults with attention deficit hyperactivity disorder. Datamonitor expects that future development focus for TC-5619 will shift towards schizophrenia, in view of Phase II data demonstrating efficacy in the treatment of cognitive dysfunction associated with the condition.
Published By Datamonitor
|
25 Mar 2011 |
|
|«
«
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
8
|
»
»|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.